Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Rebecca R, Hozak"'
Autor:
Michiel S. van der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N. Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T. Tagawa, Ulka Vaishampayan, Jeanny B. Aragon-Ching, Bernie J. Eigl, Rebecca R. Hozak, Erik R. Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M. Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Identification of biomarkers to stratify patients who might benefit from treatment is needed to optimize targeted therapies. Here, based on an analysis of the RANGE trial (NCT02426125), the authors report potentially predictive biomarkers for surviva
Externí odkaz:
https://doaj.org/article/48cfab2e04994935a36166abe99febbf
Autor:
Kazuto Nishio, MD, PhD, Takashi Seto, MD, Makoto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, MS, Kazuko Sakai, PhD, Koichi Goto, MD, PhD, Terufumi Kato, MD, Yoichi Nakanishi, MD, PhD, Toshiaki Takahashi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Katsuyuki Kiura, MD, PhD, Yuichiro Ohe, MD, PhD, Tomohide Tamura, MD, Carla Visseren-Grul, MD, Bente Frimodt-Moller, MSc, Rebecca R. Hozak, PhD, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Gosuke Homma, PhD, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100171- (2021)
Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic
Externí odkaz:
https://doaj.org/article/3e75f1f8e2034c7bb7923044f4c4d8a7
Autor:
David Planchard, Bo H. Chao, Rebecca R. Hozak, Ling Gao, Sameera R. Wijayawardana, Huzhang Mao, Dae Ho Lee, Joo-Hang Kim, Keunchil Park, Pilar Garrido, Ki Hyeong Lee, James Chih-Hsin Yang, Luis G. Paz-Ares, Helena A. Yu
Dose Adjustments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c948cb89532aa0dcb2c2b012c5ca5a5
https://doi.org/10.1158/1078-0432.22478328.v1
https://doi.org/10.1158/1078-0432.22478328.v1
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
PDF file - 23K, Waterfall plot depicting the percent change from baseline in serum in alphafetoprotein (AFP)and treatment response in HCC patients after ramucirumab monotherapy. PR, partial response; SD, stable disease; PD, progressive disease; NE, n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01898f20796700e6a757533a0e57e988
https://doi.org/10.1158/1078-0432.22448430
https://doi.org/10.1158/1078-0432.22448430
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
PDF file - 65K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b58066f9cdbc357023863f22d351570e
https://doi.org/10.1158/1078-0432.22448424
https://doi.org/10.1158/1078-0432.22448424
Autor:
David Planchard, Bo H. Chao, Rebecca R. Hozak, Ling Gao, Sameera R. Wijayawardana, Huzhang Mao, Dae Ho Lee, Joo-Hang Kim, Keunchil Park, Pilar Garrido, Ki Hyeong Lee, James Chih-Hsin Yang, Luis G. Paz-Ares, Helena A. Yu
Patient disposition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::202ce1043c77888a619f4b916e9483a5
https://doi.org/10.1158/1078-0432.22478334.v1
https://doi.org/10.1158/1078-0432.22478334.v1
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
PDF file - 76K, Fold changes in biomarker levels relative to baseline following ramucirumab infusion across study cycles. Each line indicates values for a single patient.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5375d82eda6c0d701ce99f30037a4f76
https://doi.org/10.1158/1078-0432.22448427
https://doi.org/10.1158/1078-0432.22448427
Autor:
David Planchard, Bo H. Chao, Rebecca R. Hozak, Ling Gao, Sameera R. Wijayawardana, Huzhang Mao, Dae Ho Lee, Joo-Hang Kim, Keunchil Park, Pilar Garrido, Ki Hyeong Lee, James Chih-Hsin Yang, Luis G. Paz-Ares, Helena A. Yu
Purpose:We report the final analysis of JVDL (NCT02789345), which examined the combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2-directed antibody ramucirumab in patients with T790M-positive EGFR-mutant non–small c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc2a6c98a0501382e628762860b1ae1
https://doi.org/10.1158/1078-0432.c.6529920
https://doi.org/10.1158/1078-0432.c.6529920
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
PDF file - 91K, Table S1.Fold changes in serum biomarkers relative to baseline following ramucirumabtreatment (MGH lab) Table S2: Changes in serum biomarkers relative to baseline following ramucirumab treatment (ImClonelab).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cc9b2b7500338f166849eda6e0ab3b6
https://doi.org/10.1158/1078-0432.22448421.v1
https://doi.org/10.1158/1078-0432.22448421.v1
Autor:
Keith Stuart, Dan G. Duda, Francis W. Nugent, Rakesh K. Jain, Marek Ancukiewicz, Yihuan Xu, Rebecca R. Hozak, Adarsh Joshi, Rita P. Dalal, Jonathan D. Schwartz, Weijing Sun, Jayne Gurtler, Mary Mulcahy, Richard S. Finn, Andrew X. Zhu
Purpose: To assess the efficacy and safety of the anti-VEGF receptor-2 (VEGFR-2) antibody ramucirumab as first-line therapy in patients with advanced hepatocellular carcinoma and explore potential circulating biomarkers.Experimental Design: Adults wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e5be34da83f5a5fba0780865eabc502
https://doi.org/10.1158/1078-0432.c.6521397
https://doi.org/10.1158/1078-0432.c.6521397